THERAPY DOSSIER · th-cc906b378885

MR16-1 (anti-mouse IL-6 receptor monoclonal antibody)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22369693 ↗2012Reported benefit

Blockade of interleukin-6 signaling inhibits the classic pathway and promotes an alternative pathway of macrophage activation after spinal cord injury in mice.

MouseSpinal cord injuryUnspecifiedJcl:ICRMalen = 211 mice total; MR16-1 n=85, rat IgG n=85, saline n=25, sha…Intraperitoneal50 microgram per gram body weightImmediately after injury

Model: Thoracic spinal cord injury after laminectomy

MR16-1 increased spared myelin, axonal markers and Basso Mouse Scale scores (5.0 +/- 0.3 versus 2.8 +/- 0.3), lowered Th1 cytokines and promoted M2 macrophages.

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…